Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: IL‐33 is one of the most consistently associated gene candidates for asthma identified by using a genome‐wide association study. Studies in mice and in human cells have confirmed the importance of IL‐33 in inducing type 2 cytokine production from both group 2 innate lymphoid cells (ILC2s) and TH2 cells. However, there are no pharmacologic agents known to inhibit IL‐33 release from airway cells. Objective: We sought to determine the effect of glucagon‐like peptide 1 receptor (GLP‐1R) signaling on aeroallergen‐induced airway IL‐33 production and release and on innate type 2 airway inflammation. Methods: BALB/c mice were challenged intranasally with Alternaria extract for 4 consecutive days. GLP‐1R agonist or vehicle was administered starting either 2 days before the first Alternaria extract challenge or 1 day after the first Alternaria extract challenge. Results: GLP‐1R agonist treatment starting 2 days before the first Alternaria extract challenge decreased IL‐33 release in the bronchoalveolar lavage fluid and dual oxidase 1 (Duox1) mRNA expression 1 hour after the first Alternaria extract challenge and IL‐33 expression in lung epithelial cells 24 hours after the last Alternaria extract challenge. Furthermore, GLP‐1R agonist significantly decreased the number of ILC2s expressing IL‐5 and IL‐13, lung protein expression of type 2 cytokines and chemokines, the number of perivascular eosinophils, mucus production, and airway responsiveness compared with vehicle treatment. GLP‐1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract challenge. Conclusion: These results reveal that GLP‐1R signaling might be a therapy to reduce IL‐33 release and inhibit the ILC2 response to protease‐containing aeroallergens, such as Alternaria. Graphical abstract: Figure. No caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
The genetics of asthma and allergic disease: a 21st century perspective
Ober, C., & Yao, T. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01029.x · Cited by 698
O'Hollaren, M. T., Yunginger, J. W., Offord, K. P., Somers, M. J., O'Connell, E. J., Ballard, D. J., & Sachs, M. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102073240602 · Cited by 694 · cited 1×
“In this study we performed airway challenge in mice with an extract of Alternaria alternata, an aeroallergen with protease activity that is associated with severe asthma exacerbations.(22,23) GLP-1R agonist or vehicle treatment was started either 2 days before the first Alternaria extract challenge or 1 day after the…”
Bartemes, K. R., Iijima, K., Kobayashi, T., Kephart, G. M., McKenzie, A. N., & Kita, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102832 · Cited by 549 · cited 1×
“IL-33 activates group 2 innate lymphoid cells (ILC2s) to produce the type 2 cytokines IL-5 and IL-13, which initiate innate immunity-driven allergic responses.(6,7) In addition, IL-33 polarizes naive CD4 T cells todifferentiate into effectorTH2cells,whichproduce IL-4, IL-5, and IL-13 and are responsible for adaptive i…”
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 2×
“For instance, the GLP-1R agonist exendin-4 improved atherosclerosis by reducing macrophage adhesion to endothelial cells, as well as by reducing serum glucose levels.(32) GLP-1 peptide treatment decreased irradiationor LPS-induced proinflammatory cytokine expression in the brain and astrocytes in a mouse model.”
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“For instance, GLP-1R agonist administration decreased TNF-a and IL6 production by PBMCs of obese patients with T2D(16) and diabetic mouse adipose tissue.(17) In addition, the GLP-1R agonist exendin 4 reduced serum inflammatory cytokines during LPS-induced endotoxemia,(18) liver inflammation, and aortic atherosclerosis…”
Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 1×
“GLP-1 has a role in glycemic control by inducing glucose-dependent insulin secretion from b cells and inhibiting glucagon release from a cells in the pancreas.(11,12) GLP-1 also induces weight loss by promoting satiety.”
Hogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198 · cited 1×
“GLP-1 also induces weight loss by promoting satiety.(13) Glucagon-like peptide 1 receptor (GLP-1R) agonists, such as liraglutide and exenatide, are approved by the US Food and Drug Administration (FDA) for treatment of type 2 diabetes (T2D).”
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Hristova, M., Habibovic, A., Veith, C., Janssen-Heininger, Y. M. W., Dixon, A. E., Geiszt, M., & van der Vliet, A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.003 · Cited by 141 · cited 2×
“GLP-1R agonist treatment suppresses Duox1 mRNA expression in the Alternaria extract–challenged lung DUOX1 is a critical mediator of IL-33 release from lung epithelial cells after aeroallergen challenge.(5) Therefore we measured mRNA expression of Duox1 in the lung 1 hour after Alternaria extract challenge, the time of…”
Wang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126 · cited 1×
“In addition, the GLP-1R agonist exendin 4 reduced serum inflammatory cytokines during LPS-induced endotoxemia,(18) liver inflammation, and aortic atherosclerosis in a rodent model.(19) These data indicate that GLP-1R agonists downregulate innate inflammatory responses to endotoxins or endogenous inflammatory mediators.”
Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
Reddy, I. A., Pino, J. A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R. J., Erreger, K., Wortwein, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.86 · Cited by 96
Self-citationGOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66
Cited by
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Tashiro, H., & Shore, S. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0288tr · Cited by 32
Foer, D., Amin, T., Nagai, J., Tani, Y., Feng, C., Liu, T., Newcomb, D. C., Lai, J., Hayashi, H., Snyder, W. E., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300102 · Cited by 17
Self-citation
Metadata
- Authors
- Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., Galli, A., Boyd, K. L., Niswender, K. D., & Peebles, R. S.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 142
- Issue
- 5
- Pages
- 1515-1528.e8
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2784233170
- Cited by
- 104
- References
- 18
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.